Robert Lustig, MD is bombarded by media inquiries on a regular basis. What makes him so popular? Dr. Lustig is UCSF’s childhood obesity expert and a nationally recognized leader in the field of neuroendocrinology, with an emphasis on the regulation of energy balance by the central nervous system.
Kaveh Ashrafi, PhD and his colleagues including Supriya Srinivasan, PhD generated headlines earlier this month by challenging the theory that weight gain is mostly a consequence of feeding and physical activity. By working with the worm model C. elegans, they found that the brain chemical serotonin influences two separate pathways -- one for feeding and one for fat-burning.
A UCSF faculty member for over 20 years, Mike German, MD was awarded the prestigious David Rumbough Award for Scientific Excellence by the Juvenile Diabetes Research Foundation (JDRF). This award was established in 1974 by actress Dina Merrill, in honor of her late son, David. It is the highest honor JDRF awards, and is presented annually to researchers for outstanding achievement and commitment to diabetes research and for their service to JDRF.
As the U.S. continues to struggle with its war on weight, Sherri Shafer, RD, CDE continues to spread the word about proper medical nutrition therapy for adults and children with diabetes. Last month, Sherri was interviewed by Peter Jaret, health reporter for the New York Times on “A Nutritional Approach to Managing Diabetes”.
In January, former UCSF endocrinology fellow, Saleh Adi, MD, returned to UCSF – this time as the Associate Director of Clinical Pediatrics and the Director of Pediatric Diabetes Outpatient Services. Educated in Syria, Dr. Adi completed residencies at both the California Pacific Medical Center (CPMC) and at the Veteran’s Administration Hospital.
Diabetes Center faculty member Mark Anderson, MD, PhD was one of only thirteen physicians awarded the Clinical Scientist Award in Translational Research this year by the Burroughs Wellcome Fund. This program supports established physician-scientists dedicated to translational “bench to bedside” research by providing grants of $750,000 over five years.
In January, ABC Affiliate KGO of San Francisco interviewed UCSF pediatric endocrinologist Stephen Rosenthal, MD concerning a study to help assess how a dietary supplement might prevent type 1 diabetes in high-risk infants.
After being involved in diabetes and endocrine research at UCSF for nearly 40 years – a distinguished career that includes the breakthrough cloning of the growth hormone gene and first synthesis of growth hormone, the development of the UCSF Diabetes Center, the presidency of the Endocrine Society, and election to the prestigious National Academy of Sciences – you’d think John Baxter, MD would be ready to focus on his love of fishing. Instead of retirement, Dr.
Significant progress has been made in the past several years in improving the results of pancreatic islet transplantation for type 1 diabetics. Here at UCSF, we are very pleased with our success rate using a new enzyme that has helped to ensure islet viability through the transplant process.
Even the popular press is excited about recent developments involving anti-CD3, a potential type 1 therapy with strong ties to UCSF. In a recent issue of FORBES Magazine, senior editor Robert Langreth reveals the long history of anti-CD3 -- a monoclonal antibody that stops beta cell destruction.
Thanks to a generous gift made possible by a family whose lives have been impacted by type 1 diabetes, the Mary B. Olney MD / KAK Chair in Pediatric Diabetes and Clinical Research has been awarded to Steve Gitelman, MD, Director of the UCSF Pediatric Diabetes Program.
While leading the Department of Biochemistry and Biophysics and the Hormone Research Institute, William J. Rutter, PhD helped UCSF to make some of its most important contributions in biotechnology -- including the cloning of the genes for insulin and human growth hormone. It was these discoveries that spurred the creation of the world’s first biotech company, Genentech Inc., and Chiron Corp., the company Dr. Rutter co-founded.
To take a promising drug to market, it costs on average $500 million. Academic research institutions such as UCSF excel in conducting basic research and early stage human clinical trials, however, for cost reasons it is important that promising therapies are picked up by private industry.